Grants per year
Search results
-
Active
-
Prot #M22-003: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Karmali, R. (PD/PI)
11/22/24 → 11/22/27
Project: Research project
-
Prot #NU 23H05: Phase II, Single arm, Open label, study of the combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients
Karmali, R. (PD/PI)
9/23/24 → 9/23/27
Project: Research project
-
Prot #GO44145: A Phase III, Multicenter, Randomized, Open-Label Study Comparing The Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA
Karmali, R. (PD/PI)
7/18/24 → 5/31/29
Project: Research project
-
Prot #CRG‐022‐101: An Open‐label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG‐022, a CD22‐Directed Autologous Chimeric Antigen Receptor (CAR) T‐cell Therapy in Patients With Relapsed/Refractory Large B‐Cell Lymphoma After CD19‐Dire
Karmali, R. (PD/PI)
Novella Clinical, LLC, CARGO Therapeutics, Inc.
5/24/24 → 4/30/26
Project: Research project
-
Prot #KT-US-472-0141: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleuce
Karmali, R. (PD/PI)
ICON Clinical Research Limited, Kite Pharma, Inc.
1/22/24 → 1/22/27
Project: Research project
-
Prot #KT‐US‐484‐0136: An Adaptive Phase 3, Randomized, Open‐Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel Versus Standard of Care Therapy as First‐Line Therapy in Subjects with High‐Risk Large B‐Cell Lymphoma (ZUMA
Karmali, R. (PD/PI)
ICON Clinical Research Limited, Kite Pharma, Inc.
11/7/23 → 11/7/26
Project: Research project
-
Prot #KT‐US‐471‐0140: Expanded Access Study for the Treatment of Patients with Commercially Out‐of‐Specification Axicabtagene Ciloleuce
Karmali, R. (PD/PI)
ICON Clinical Research Limited, Kite Pharma, Inc.
9/14/23 → 9/14/26
Project: Research project
-
Y24-28 Carryforward
Johnson, J. L. P. (Other), Karmali, R. (Other), Kirsammer, G. (Other) & Lorch, J.H.-M. (Other)
8/1/23 → 7/31/25
Project: Research project
-
Prot #NU MSK22H05: Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)
Karmali, R. (PD/PI)
Memorial Sloan Kettering Cancer Center, BeiGene Ltd.
3/20/23 → 3/20/26
Project: Research project
-
Prot #M-2018-344: A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Dif
Karmali, R. (PD/PI)
Parexel, Miltenyi Biomedicine GmbH
8/12/22 → 8/12/25
Project: Research project
-
Prot #JCAR017-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That Is Nonconforming for Commercial Release
Karmali, R. (PD/PI)
DrugDev Inc., Juno Therapeutics, Inc.
2/3/21 → 1/30/26
Project: Research project
-
Prot #NU MSK19H03: A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)
Karmali, R. (PD/PI)
Memorial Sloan Kettering Cancer Center
9/17/20 → 9/17/26
Project: Research project
-
Prot #JCAR017-FOL-001: A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)
Karmali, R. (PD/PI)
ICON Clinical Research, LLC, Celgene Corporation
7/27/20 → 7/27/26
Project: Research project
-
Prot #JCAR017-BCM-003: A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TR
Karmali, R. (PD/PI)
ICON Clinical Research, LLC, Celgene Corporation
10/21/19 → 10/21/25
Project: Research project